SNX27 Antibody

What is SNX27 and what cellular functions does it perform?

SNX27 is a 61.3 kilodalton protein that specifically binds and directs sorting of transmembrane proteins containing PDZ-binding motifs at their C-terminus. Following interaction with target transmembrane proteins, SNX27 associates with the retromer complex, preventing cargo entry into the lysosomal pathway and promoting retromer-tubule based plasma membrane recycling . It functions primarily in the retrograde transport from endosomes to plasma membrane, a critical trafficking pathway that ensures proper recycling of internalized transmembrane proteins instead of their degradation in lysosomes . SNX27 also interacts with the WASH complex and membranes containing phosphatidylinositol-3-phosphate (PtdIns(3P)) . Additionally, it may participate in establishing natural killer cell polarity and recruits CYTIP to early endosomes .

What alternative nomenclature exists for SNX27?

Researchers should be aware that SNX27 may also be referenced in the literature using several alternative names:

• MY014

• Mrt1

• Methamphetamine-responsive transcript 1

• Sorting nexin family member 27

Understanding these alternative designations is critical when conducting literature searches or database queries to ensure comprehensive retrieval of relevant research.

What species-specific orthologs of SNX27 have been characterized?

Based on gene sequence homology, SNX27 orthologs have been identified in multiple species including:

• Canine (dog)

• Porcine (pig)

• Monkey (non-human primates)

• Mouse

• Rat

What criteria should guide SNX27 antibody selection for specific applications?

When selecting SNX27 antibodies, researchers should consider:

• Application compatibility: Verify that the antibody has been validated for your specific application (WB, ELISA, IHC, IF, FCM, IP)

• Species reactivity: Confirm reactivity with your experimental model organism (human, mouse, rat, etc.)

• Clonality considerations:

  • Monoclonal antibodies (e.g., clone 1C6) offer high specificity and reproducibility

  • Polyclonal antibodies provide broader epitope recognition and potentially stronger signals

• Target region: Select antibodies targeting functionally relevant domains based on your research question (e.g., PDZ domain for protein interaction studies)

• Conjugation options: Consider pre-conjugated antibodies (HRP, FITC, biotin) for specialized applications to eliminate secondary antibody steps

How should researchers validate SNX27 antibody specificity?

A rigorous validation approach includes:

• Western blot analysis with positive controls (verified in HepG2, Jurkat, A549 cell lysates; mouse brain tissue; rat heart and liver tissues)

• Expected banding pattern assessment:

  • Primary bands expected at 62 kDa and 53 kDa

  • Additional bands at 60 kDa and 28 kDa may represent alternative isoforms

• Negative controls implementation:

  • SNX27 knockout/knockdown samples

  • Secondary antibody-only controls

  • Peptide competition assays with the immunizing peptide (amino acids 458-497 for some antibodies)

• Immunohistochemical validation using tissues with known SNX27 expression (e.g., human small intestine)

• Cross-validation with multiple antibodies targeting different epitopes

What positive and negative controls are recommended for SNX27 antibody experiments?

What are the optimal conditions for Western blot detection of SNX27?

For maximum sensitivity and specificity in Western blot:

• Sample preparation:

  • Include phosphatase inhibitors to preserve post-translational modifications

  • Use detergent-containing lysis buffers (e.g., RIPA with 0.1% SDS) to effectively solubilize membrane-associated SNX27

• Electrophoresis and transfer:

  • 10% SDS-PAGE gels provide optimal resolution for 53-62 kDa protein range

  • Semi-dry transfer: 15V for 30 minutes or wet transfer: 100V for 60 minutes

• Antibody incubation:

  • Primary antibody dilution: 1:500-1:5000 (optimize for each antibody)

  • Secondary antibody: Anti-rabbit IgG-HRP at 1:50000 dilution

  • Consider overnight incubation at 4°C for primary antibody to improve sensitivity

• Expected results:

  • Major bands at 62 kDa and 53 kDa

  • Potential minor bands at 60 kDa and 28 kDa depending on cell/tissue type

What protocol modifications enhance immunohistochemical detection of SNX27?

For optimal IHC results:

• Tissue preparation:

  • Formalin-fixed, paraffin-embedded sections (4-6 μm thickness)

  • Freshly prepared sections yield better results than archived slides

• Antigen retrieval methods:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Pressure cooker treatment (125°C for 3 minutes) may improve staining intensity

• Antibody parameters:

  • Dilution range: 1:20-1:200 (optimize for each antibody)

  • Incubation time: 1-2 hours at room temperature or overnight at 4°C

• Signal development:

  • DAB chromogen for brightfield microscopy

  • Fluorophore-conjugated secondary antibodies for immunofluorescence

  • TSA amplification system for low-abundance detection

How can immunofluorescence protocols be optimized for SNX27 co-localization studies?

For high-quality co-localization analyses:

• Fixation optimization:

  • 4% paraformaldehyde (10-15 minutes) preserves membrane architecture

  • Methanol fixation (-20°C for 10 minutes) may enhance some epitope accessibility

• Permeabilization:

  • 0.1-0.3% Triton X-100 for balanced permeabilization

  • 0.1% saponin for milder permeabilization that better preserves membrane structures

• Co-staining strategies:

  • For endosomal markers: pair SNX27 antibodies with EEA1 (early endosomes), Rab11 (recycling endosomes), or VPS35 (retromer)

  • Use antibodies raised in different host species to avoid cross-reactivity

  • Sequential staining protocol for challenging combinations

• Imaging considerations:

  • Confocal microscopy with sequential scanning to prevent bleed-through

  • Super-resolution techniques (STED, SIM) for detailed co-localization analysis

  • Consistent exposure settings across experimental conditions

How can researchers address weak or absent signals in Western blots?

When encountering poor signal detection:

• Protein extraction optimization:

  • Ensure complete lysis with appropriate detergents

  • Include protease inhibitors to prevent degradation

  • Consider membrane fraction enrichment techniques

• Loading and transfer adjustments:

  • Increase protein loading amount (30-50 μg per lane)

  • Verify transfer efficiency with reversible staining (Ponceau S)

  • Optimize transfer conditions for higher molecular weight proteins

• Antibody parameters:

  • Increase primary antibody concentration (try 1:250 if 1:500 fails)

  • Extend incubation time to overnight at 4°C

  • Use more sensitive detection systems (enhanced chemiluminescence)

• Blocking optimizations:

  • Try alternative blocking agents (5% BSA instead of milk for phosphorylated epitopes)

  • Reduce blocking stringency if epitope accessibility is compromised

What strategies address non-specific bands or high background in SNX27 detection?

To improve specificity:

• For non-specific bands:

  • Increase antibody dilution (1:2000-1:5000)

  • Use monoclonal antibodies like clone 1C6 for higher specificity

  • Implement more stringent washing conditions (increased salt concentration)

  • Confirm that bands at 62, 60, 53, and 28 kDa may represent legitimate isoforms

• For high background:

  • Extend blocking time (2 hours at room temperature)

  • Increase wash duration and frequency (5 washes x 5 minutes)

  • Add 0.05% Tween-20 to antibody dilution buffers

  • Consider alternative blocking agents (gelatin, casein)

• For membrane-related issues:

  • Use fresh transfer buffers

  • Clean electrophoresis equipment thoroughly

  • Pre-adsorb antibodies with non-relevant tissue lysates

How can inconsistent immunostaining patterns be resolved?

When facing variability in staining:

• Sample preparation standardization:

  • Standardize fixation times and conditions

  • Process all experimental samples simultaneously

  • Maintain consistent antigen retrieval conditions

• Protocol consistency:

  • Use the same antibody lot across experiments

  • Prepare fresh working solutions for each experiment

  • Implement temperature-controlled incubation conditions

• Controls implementation:

  • Include internal positive and negative controls in every experiment

  • Use standardized positive tissue sections as staining controls

  • Implement automated staining platforms for technical consistency

• Quantification approaches:

  • Establish objective analysis parameters

  • Use automated image analysis software with consistent thresholds

  • Implement blinded scoring by multiple observers

How can SNX27 antibodies be used to investigate protein-protein interactions?

For examining SNX27's interactome:

• Co-immunoprecipitation (Co-IP):

  • Use SNX27 antibodies to pull down native protein complexes

  • Identify interaction partners through Western blot or mass spectrometry

  • Investigate retromer component associations (VPS35, VPS26, VPS29)

  • Detect PDZ-binding motif-containing cargo proteins

• Proximity ligation assay (PLA):

  • Visualize protein interactions in situ with single-molecule sensitivity

  • Quantify SNX27 interactions with specific cargo proteins

  • Assess interaction dynamics under various treatment conditions

• FRET/BRET approaches:

  • Monitor real-time interactions in living cells

  • Assess interaction kinetics and binding dynamics

  • Evaluate effects of mutations on protein-protein interactions

• Cross-linking approaches:

  • Stabilize transient interactions prior to immunoprecipitation

  • Identify weak or transient binding partners

  • Map interaction domains through site-specific cross-linking

What approaches enable the study of SNX27's role in neurological disorders?

For neurological disease investigations:

• Expression analysis:

  • Compare SNX27 levels in control versus diseased brain tissues

  • Correlate expression with disease severity or progression markers

  • Assess region-specific alterations in complex neurological conditions

• Trafficking studies:

  • Monitor trafficking of disease-relevant cargo (e.g., AMPA receptors, APP)

  • Evaluate SNX27-dependent recycling in patient-derived neurons

  • Assess effects of disease-causing mutations on SNX27 function

• Therapeutic screening:

  • Evaluate compounds that modulate SNX27 expression or function

  • Assess restoration of trafficking defects in disease models

  • Monitor SNX27-cargo interactions following treatment

• In vivo applications:

  • Immunohistochemical analysis of SNX27 in animal models of neurodegeneration

  • Correlation of SNX27 alterations with behavioral phenotypes

  • Evaluation of SNX27 restoration strategies on disease outcomes

How can researchers apply SNX27 antibodies to study retromer-mediated endosomal sorting?

For mechanistic studies of retromer function:

• Structural organization analysis:

  • Immunofluorescence co-localization with retromer components

  • Super-resolution microscopy of SNX27-retromer assemblies

  • Quantification of SNX27-positive endosomal tubules

• Cargo selection mechanisms:

  • Immunoprecipitation of SNX27-cargo complexes

  • Analysis of PDZ domain interactions with C-terminal motifs

  • Competitive binding studies with multiple cargo proteins

• Membrane recruitment dynamics:

  • Live-cell imaging with labeled SNX27 antibodies

  • FRAP analysis of SNX27 membrane association/dissociation

  • Quantification of PtdIns(3P)-dependent recruitment

• Functional consequences of manipulation:

  • Effects of SNX27 depletion on cargo fate

  • Rescue experiments with wild-type versus mutant SNX27

  • Quantitative analysis of plasma membrane receptor levels

How are SNX27 antibodies being applied in emerging cancer research?

Recent applications in cancer biology include:

• Expression profiling:

  • Immunohistochemical analysis across tumor types and stages

  • Correlation with patient outcomes and treatment response

  • Identification of SNX27 as a potential prognostic marker

• Drug resistance mechanisms:

  • SNX27's role in trafficking drug efflux transporters (e.g., ABCC4)

  • Correlation between SNX27 expression and chemoresistance

  • Targeting SNX27-dependent recycling to overcome resistance

• Signaling pathway integration:

  • SNX27's impact on receptor tyrosine kinase trafficking

  • Effects on downstream signaling cascade activation

  • Potential as a therapeutic target in specific cancer subtypes

• Metabolic reprogramming:

  • SNX27's influence on nutrient transporter recycling

  • Role in sustaining altered metabolic demands of cancer cells

  • Potential metabolic vulnerabilities from SNX27 modulation

What cutting-edge microscopy techniques are enhancing SNX27 localization studies?

Advanced imaging approaches include:

• Super-resolution microscopy:

  • STORM/PALM: Nanoscale resolution of SNX27-positive endosomal domains

  • SIM: Enhanced resolution of tubular endosomal networks

  • STED: Detailed visualization of SNX27-retromer assemblies

• Live-cell imaging innovations:

  • Lattice light-sheet microscopy for low-phototoxicity 3D imaging

  • Single-particle tracking of SNX27-positive vesicles

  • Optogenetic manipulation of SNX27 recruitment

• Correlative light-electron microscopy (CLEM):

  • Ultrastructural context of SNX27-labeled compartments

  • Immunogold labeling for precise localization at EM resolution

  • 3D electron tomography of SNX27-positive tubular networks

• Expansion microscopy:

  • Physical magnification of samples for enhanced resolution

  • Improved visualization of complex endosomal networks

  • Compatible with standard confocal microscopy equipment

How can researchers leverage emerging single-cell approaches with SNX27 antibodies?

Innovative single-cell applications include:

• Single-cell imaging:

  • High-content screening of SNX27 expression and localization

  • Correlation with cellular phenotypes at individual cell level

  • Machine learning-based classification of trafficking patterns

• Spatial transcriptomics integration:

  • Correlation of SNX27 protein levels with local transcriptome

  • Identification of co-regulated gene networks

  • Tissue context-dependent regulation of SNX27 function

• Mass cytometry (CyTOF):

  • Multi-parameter analysis of SNX27 levels alongside other markers

  • Identification of distinct cellular subpopulations

  • Correlation with differentiation or activation states

• Microfluidic approaches:

  • Single-cell protein expression quantification

  • Trafficking analysis in isolated primary cells

  • Correlation of SNX27 function with cellular response to stimuli

How does SNX27 expression pattern vary across different tissues and cellular contexts?

Tissue-specific expression patterns include:

• Brain:

  • High expression in neurons, particularly in hippocampus and cortex

  • Enriched at postsynaptic densities

  • Critical for glutamate receptor trafficking

• Immune system:

  • Expressed in lymphocytes and natural killer cells

  • Involved in immune synapse formation

  • Regulates CYTIP recruitment to endosomes

• Kidney:

  • Present in proximal tubule epithelial cells

  • Regulates trafficking of ion transporters

  • Implicated in kidney disease pathophysiology

• Heart:

  • Detected in cardiomyocytes

  • Potential role in cardiac function

  • Associated with cardiovascular disease mechanisms

What disease associations have been established for SNX27 dysfunction?

SNX27 has been implicated in multiple pathological conditions:

• Neurological disorders:

  • Down syndrome: Reduced SNX27 expression contributes to synaptic dysfunction

  • Alzheimer's disease: Altered trafficking of amyloid precursor protein

  • Learning disorders: Impaired glutamate receptor recycling

• Metabolic conditions:

  • Glucose transporter trafficking defects

  • Potential implications for diabetes and obesity

  • Regulation of insulin receptor trafficking

• Cardiovascular diseases:

  • Altered trafficking of ion channels and transporters

  • Potential role in cardiac hypertrophy

  • Association with heart failure mechanisms

• Cancer:

  • Altered expression in multiple tumor types

  • Involvement in chemotherapy resistance

  • Regulation of growth factor receptor recycling

How do SNX27 antibodies facilitate comparative studies across species models?

For cross-species research:

• Epitope conservation analysis:

  • Human and mouse SNX27 share approximately 93% amino acid identity

  • The PDZ domain shows highest conservation across species

  • C-terminal regions display greater variability

• Validation strategies:

  • Test antibody cross-reactivity on lysates from multiple species

  • Verify subcellular localization patterns across species

  • Confirm functional conservation through rescue experiments

• Application considerations:

  • Use antibodies targeting highly conserved epitopes for cross-species studies

  • Optimize antibody concentrations for each species

  • Validate knockout/knockdown controls in each model organism

• Translational implications:

  • Connect findings across model systems to human disease

  • Establish conservation of molecular mechanisms

  • Identify species-specific variations that may impact therapeutic approaches